Becotatug vedotin
As of the edition of 20 October 2026, Becotatug vedotin is an antibody drug conjugate: in active development; acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 57, 1 stopped early
- Disease areas
- Cancer; Ear, nose and throat; Mouth and teeth; Digestive system; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 3 | 0 |
| Phase 2 | 46 | 3 | 42 | 1 |
| Phase 3 | 7 | 0 | 7 | 0 |
| All trials | 57 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Lepu Biopharma | Lead sponsor of trials | 2018 to now |